Folate‐conjugated herpes simplex virus for retargeting to tumor cells

Background Herpes simplex virus type 1 (HSV‐1)‐mediated oncolytic therapy is a promising cancer treatment modality. However, viral tropism is considered to be one of the major stumbling blocks to the development of HSV‐1 as an anticancer agent. Methods The surface of oncolytic HSV‐1 G207 was covalently modified with folate‐poly (ethylene glycol) conjugate (FA‐PEG). The specificities and tumor targeting efficiencies of modified or unmodified G207...